Organogenesis (ORGO) Competitors $3.25 -0.22 (-6.34%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.19 -0.06 (-1.85%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. ANIP, MESO, OCUL, BGM, GPCR, AMPH, CALT, AUPH, CVAC, and MLYSShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors ANI Pharmaceuticals Mesoblast Ocular Therapeutix Qilian International Holding Group Structure Therapeutics Amphastar Pharmaceuticals Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals CureVac Mineralys Therapeutics Organogenesis (NASDAQ:ORGO) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Do analysts rate ORGO or ANIP? Organogenesis presently has a consensus price target of $5.50, indicating a potential upside of 69.23%. ANI Pharmaceuticals has a consensus price target of $80.13, indicating a potential upside of 27.63%. Given Organogenesis' higher possible upside, equities analysts plainly believe Organogenesis is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer ORGO or ANIP? In the previous week, Organogenesis had 7 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 13 mentions for Organogenesis and 6 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.58 beat Organogenesis' score of 1.37 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders hold more shares of ORGO or ANIP? 49.6% of Organogenesis shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 33.0% of Organogenesis shares are held by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ORGO or ANIP more profitable? ANI Pharmaceuticals has a net margin of -1.28% compared to Organogenesis' net margin of -1.62%. ANI Pharmaceuticals' return on equity of 15.87% beat Organogenesis' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.62% -2.69% -1.63% ANI Pharmaceuticals -1.28%15.87%6.88% Does the MarketBeat Community favor ORGO or ANIP? ANI Pharmaceuticals received 344 more outperform votes than Organogenesis when rated by MarketBeat users. However, 65.99% of users gave Organogenesis an outperform vote while only 64.19% of users gave ANI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOrganogenesisOutperform Votes9765.99% Underperform Votes5034.01% ANI PharmaceuticalsOutperform Votes44164.19% Underperform Votes24635.81% Which has more risk and volatility, ORGO or ANIP? Organogenesis has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Which has stronger valuation and earnings, ORGO or ANIP? ANI Pharmaceuticals has higher revenue and earnings than Organogenesis. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$458.76M0.90$4.95M-$0.17-19.12ANI Pharmaceuticals$674.07M2.02$18.78M-$1.27-49.43 SummaryANI Pharmaceuticals beats Organogenesis on 12 of the 19 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$412.28M$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-54.178.7827.1420.06Price / Sales0.90255.49419.32157.08Price / Cash15.7265.8538.2534.64Price / Book1.546.557.064.70Net Income$4.95M$143.93M$3.23B$247.88M7 Day Performance12.85%3.84%2.83%2.63%1 Month Performance9.06%11.20%9.02%6.36%1 Year Performance23.11%4.18%31.36%14.05% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.6333 of 5 stars$3.25-6.3%$5.50+69.2%+20.4%$412.28M$458.76M-54.17950Positive NewsAnalyst RevisionANIPANI Pharmaceuticals4.2288 of 5 stars$61.91+5.4%$80.13+29.4%-3.3%$1.34B$674.07M-112.56600High Trading VolumeMESOMesoblast2.3496 of 5 stars$10.38-2.4%$18.00+73.4%+62.8%$1.33B$5.67M0.0080News CoverageAnalyst RevisionOCULOcular Therapeutix3.8423 of 5 stars$8.11+1.2%$16.25+100.4%+75.7%$1.29B$59.65M-6.14230Positive NewsBGMQilian International Holding GroupN/A$12.90-3.7%N/AN/A$1.25B$25.10M0.00298Positive NewsGap UpGPCRStructure Therapeutics2.5 of 5 stars$21.79+0.1%$79.86+266.5%-54.6%$1.25BN/A-29.45136News CoveragePositive NewsAnalyst RevisionAMPHAmphastar Pharmaceuticals3.6678 of 5 stars$25.38-1.3%$32.33+27.4%-36.7%$1.20B$730.66M8.461,620CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.3372 of 5 stars$7.96+1.5%$11.50+44.5%+45.8%$1.08B$247.30M-53.06300Positive NewsAnalyst RevisionCVACCureVac4.4171 of 5 stars$4.63+3.6%$11.00+137.6%-4.2%$1.04B$523.70M8.42880Positive NewsMLYSMineralys Therapeutics3.3374 of 5 stars$15.70+0.8%$38.00+142.0%+19.7%$1.02BN/A-4.3128Positive NewsAnalyst Forecast Related Companies and Tools Related Companies ANI Pharmaceuticals Alternatives Mesoblast Alternatives Ocular Therapeutix Alternatives Qilian International Holding Group Alternatives Structure Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives Aurinia Pharmaceuticals Alternatives CureVac Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORGO Stock Free ORGO Stock Alerts